You say you have no option, but by making the post that you have you are giving a negtive option, where are your facts.
Facts:
Quidel Corp. Earnings -2: 3Q, 9-Mos Fincl Table
Quidel Corp. - San Diego
Quar Dec. 31:
1996 1995
Revenues $12,437,000 $9,253,000
Net income 1,805,000 422,000
Avg shrs 22,374,000 23,056,000
Shr earns:
Net income .08 .02
9 Months:
Revenues 31,817,000 26,133,000
Net income 2,206,000 446,000
Avg shrs 22,604,000 22,550,000
Shr earns:
Net income .10 .02
Quidel Corp. (QDEL) develops and manufactures rapid immunodiagnostic products for the detection of human medical conditions and illnesses.
"Dow Jones News Service"
"Copyright(c) 1997, Dow Jones & Company, Inc."
Procter & Gamble To Sell Quidel H. Pylori Test
CINCINNATI (Dow Jones)--Procter & Gamble Co. (PG) reached a one-year agreement to sell Quidel Corp.'s (QDEL) QuickVue One-Step H. pylori test.
In a press release, Procter & Gamble said its sales people will promote the test when making calls on physicians to communicate the benefits of its own Helidac Therapy.
QuickVue is a serological, or blood-based, test to diagnose H. pylori infections.
Helidac Therapy treats patients with active duodenal ulcers associated with H. pylori infections by combining three drugs; bismuth subsalicylate, metronidazole and tetracycline hydrochloride.
Procter & Gamble said Quidel will provide it with free two-test kit samples of Quidel's diagnostic kit.
Quidel Corp. develops, manufactures and markets immunodiagnostic products.
"Dow Jones News Service"
"Copyright(c) 1997, Dow Jones & Company, Inc."
P&G and QUIDEL To Promote H. pylori Duodenal Ulcer Products To Physicians
CINCINNATI and SAN DIEGO -- For the 3 million adults in the United States who suffer from an active duodenal ulcer, here's a New Year's resolution worth keeping: make 1997 the year you get rid of it for good.
Making good on that resolution should be even easier this year, thanks to a co-promotion agreement announced today by The Procter & Gamble Company (NYSE: PG) and QUIDEL Corporation (Nasdaq: QDEL).
The two companies said they have formed a strategic collaboration to promote QUIDEL's QuickVue(R) One-Step H. Pylori Test, an in-office diagnostic test, and P&G's Helidac(R) Therapy (bismuth subsalicylate, metronidazole and tetracycline hydrochloride), along with an H-2 acid suppression medication, as part of a disease management program to help physicians better identify and treat patients with active duodenal ulcers associated with H. pylori infection.
Specifically, P&G's pharmaceutical sales force will promote QUIDEL's QuickVue test when making calls on physicians to communicate the benefits of its Helidac Therapy. In turn, QUIDEL will provide P&G with two-test kit samples of its diagnostic kit. The agreement between the two companies is valid for up to one year, and is renewable. No additional terms were disclosed.
Currently, physicians may choose from a range of options to diagnose H. pylori infections. Some tests rely on tissue samples removed from the stomach or intestine through an invasive and costly endoscopic procedure, which may require a hospital stay. Other tests rely on breath samples which require lab analysis, which takes time, delaying initiation of treatment.
However, serological or blood-based tests, like QUIDEL's QuickVue, are seen as quick pre-treatment diagnostic methods for identifying suspected H. pylori infections. These tests typically are conducted in the doctor's office, and are cost-effective and quick for the patient and physician.
"This is good news for busy physicians and busy patients," said David Peura, MD, chief, division of gastroenterology, University of Virginia Health Sciences Center, Charlottesville, VA. "Now, in one office visit, a physician can easily, effectively and economically diagnose a patient with a suspected H. pylori infection and prescribe an effective ulcer eradication therapy to help them treat it. This saves everyone time and money."
First And Only Kit Cleared To Be Used Broadly By Physicians
QUIDEL's QuickVue is the first and only serological test that has received waived status from the U.S. Centers for Disease Control (CDC). This means it is more broadly available to physicians nationwide who routinely use in-office diagnostic tests to confirm medical conditions. Diagnostic tests that don't have waived status require increased quality control testing, and are available to far fewer physicians.
In addition, QUIDEL's QuickVue test is the only one-step whole blood test intended for in-office use. Test results are available in 10 minutes from a simple finger-stick blood sample. Clinical studies prove the test is highly accurate and provides results with 93% agreement to laboratory methods. The test costs physicians under $20.
P&G's Helidac Therapy Off To A Good Start; Achieves "Preferred" Status
With Managed Care Organizations
After only four weeks on the market, P&G's Helidac Therapy has produced solid results to date. P&G said that Helidac Therapy achieved its four-week retail distribution goal in just one week.
Helidac Therapy also has received preferred formulary status at many managed care organizations. This means that after diagnosing a patient with an active duodenal ulcer, a physician is recommended to use Helidac Therapy, in conjunction with an H-2 acid suppression medication, before other approved H. pylori eradication therapies are considered.
In fact, PCS, the nation's largest pharmacy benefit management organization with responsibility for 56 million patients, has included Helidac Therapy in its Clinical Formulary And Prescribing Guidelines.
P&G's Helidac Therapy combines three drugs: bismuth subsalicylate, metronidazole and tetracycline hydrochloride in a unique, cube-shaped kit designed for patient compliance. Helidac Therapy is priced wholesale at $77. Even when dosed with an H-2 acid suppression medication, Helidac Therapy is priced up to 50% less than other approved therapies.
In pivotal clinical trials, among all evaluable patients, Helidac Therapy, when used in conjunction with an H-2 acid suppression medication, achieved eradication rates of up to 82%. Additionally, 91% of all evaluable patients did not have an ulcer recurrence one year after treatment.
Helidac Therapy also is well-tolerated; the most common side effects include nausea (10%), diarrhea (5%) and abdominal pain (3%).
As with any prescription drug, however, Helidac Therapy is not for all patients. Helidac Therapy is contraindicated in pregnant or nursing women, pediatric patients and patients with renal or hepatic impairment, and in those with known hypersensitivity to bismuth subsalicylate, metronidazole, tetracycline or any related derivatives.
It is recommended that all patients not eradicated of H. pylori following Helidac Therapy plus an H-2 acid suppression medication should be considered to have H. pylori resistant to metronidazole. Patients who fail therapy should not be retreated with a regimen containing metronidazole.
Background information: QUIDEL, P&G
QUIDEL Corporation discovers, develops, manufactures and markets rapid immunodiagnostic products for point-of-care detection of human medical conditions and illnesses. These products provide simple, accurate and cost- effective diagnoses for acute and chronic conditions in the areas of reproductive and women's health, infectious diseases, allergies and autoimmune disorders.
QUIDEL's products are sold to professionals in the physician's office and clinical laboratory, and to consumers through retail drug stores. For more information, visit the company's web site at quidel.com.
P&G makes and markets prescription and over-the-counter products in 60 countries. P&G's focus for prescription drugs is on anti-infective, cardiac and musculo-skeletal therapies. In OTC health care, P&G's leading brands include Vicks. cough/cold/flu and allergy products, Crest(R), Scope(R), Metamucil(R) and Pepto-Bismol(R).
P&G is also actively partnering with a range of leading pharmaceutical and biotechnology companies to develop and market innovative therapies. P&G had sales of $35 billion in fiscal 1995-96.
To receive product information on P&G's Helidac Therapy, call toll-free 1-888-4HELIDAC (1-888-443-5432).
This news release contains forward-looking statements regarding QUIDEL and Procter & Gamble and their future sales-related activities. Actual results could differ materially from those described or implied in this news release as a result of a number of factors, including, but not limited to, the development of new products in conjunction with partners, any adverse actions by the Companies' distributors, competitive products, other economic factors affecting the Companies' markets, the degree of acceptance that products achieve, and seasonality and other factors discussed in the Companies' Annual Reports on Form 10-K and subsequent quarterly reports on Form 10-Q. Copies of Forms 10-K and 10-Q are available from each Company upon request.
/NOTE TO EDITORS: Background: H. pylori and ulcer disease
* H. pylori bacteria was first successfully cultured in 1982 by Barry J.
Marshall, MD and J. Robin Warren, MD, in Perth, Australia. Since the turn of the century, pathologists suspected viral or bacterial organisms were present in the stomach, however, no one had succeeded in growing the organism.
* While it's widely acknowledged that H. pylori is associated with ulcer
disease, it's not as clear how the infection leads to ulcers. It's believed that the organism causes inflammation in the stomach and, over time, may lead to damage of the stomach lining.
* A vast number of people worldwide are infected with H. pylori, but most
-- probably 75% -- never develop symptoms.
* In the United States, the overall infection rate ranges from less than
20% by age 20 to more than 60% by age 60. Physicians traditionally relied on invasive, time-consuming endoscopic tests to diagnose H. pylori infections. However, new in-office blood tests, like QUIDEL's QuickVue, offer physicians speed, convenience and low cost.
* In 1996, the U.S. Food and Drug Administration cleared, separately,
three multi-drug combination therapies to eradicate H. pylori infections.
P&G's Helidac Therapy is the only active duodenal ulcer therapy with packaging designed for patient compliance -- with features like blister card dosing and easy-to-read patient information. In addition, P&G's Helidac Therapy received the first-ever seal from the Healthcare Compliance Packaging Council for its unique packaging./
/CONTACT: James J. Schwartz, Manager, Public Relations, of P&G,
513-945-8055; or Steven T. Frankel, President and Chief Executive Officer,
619-552-7902, or Steve Burke, Chief Financial Officer, 619-552-7960, both of
QUIDEL/
"Copyright(c) 1997, PR Newswire"
"Provided by Dow Jones & Company, Inc."
Quidel Gets MedPartners Diagnostic Test Supply Pact
SAN DIEGO (Dow Jones)--Quidel Corp. (QDEL) received a three-year contract to supply MedPartners Inc.'s (MDM) physician groups with its rapid diagnostic tests.
Terms were not disclosed.
Quidel discovers, develops, manufactures, and markets rapid immunodiagnostic products.
MedPartners develops, consolidates and manages healthcare delivery systems.
"Dow Jones News Service"
"Copyright(c) 1996, Dow Jones & Company, Inc."
Quidel, Bayer Corp. In Development, Supply Pact
SAN DIEGO, Calif. (Dow Jones)--Quidel Corp. (QDEL) signed a multi-year development and supply agreement with Bayer Corp.'s Business Group Diagnostics.
Financial terms were not disclosed.
Bayer Corp. is a unit of Bayer AG (BAYZY).
In a press release, the companies said Quidel will develop immunodiagnostic tests for use with Bayer's Clinitek analyzers.
The Clinitek analyzers are urine chemistry systems.
Quidel Corp., San Diego, develops and makes immunodiagnostic products.
Bayer's Business Group Diagnostics is based in Tarrytown, N.Y.
"Dow Jones News Service"
"Copyright(c) 1996, Dow Jones & Company, Inc."
Just a few facts:
Jim |
